Buscar

01/08/2024 PHASE 2 EFFICACY AND SAFETY OF RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Querol, L, Lewis, RA, Hartung, HP, Van Doorn, PA, Wallstroem, E, Auwarter, K, Luo, XD, Alonso-Alonso, M, Atassi, N, Hughes, RAC. PHASE 2 EFFICACY AND SAFETY OF RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024 PHASE 2 TRIAL OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: QUALITY-OF-LIFE AND FATIGUE
Van Doorn, PA, Querol, L, Hartung, HP, Hughes, RAC, Orsini, M, Hakimi-Hawken, N, Minor, C, Msihid, J, Alonso-Alonso, M, Atassi, N, Lewis, R. PHASE 2 TRIAL OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: QUALITY-OF-LIFE AND FATIGUE. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024 PHASE 2 TRIAL OF RILIPRUBART IN CIDP: EFFECT ON COMPLEMENT BIOMARKERS AND NEUROFILAMENT LIGHT CHAIN
Querol, L, Lewis, RA, Van Doorn, PA, Hughes, RAC, Storek, M, Rajagopal, V, Chow, T, Luo, XD, Alonso-Alonso, M, Atassi, N, Hartung, HP. PHASE 2 TRIAL OF RILIPRUBART IN CIDP: EFFECT ON COMPLEMENT BIOMARKERS AND NEUROFILAMENT LIGHT CHAIN. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024 CLINICAL AND GENETIC SPECTRUM OF PATIENTS WITH BAG3-RELATED NEUROMUSCULAR DISORDERS IN EUROPE
Fernandez-Eulate, G, Gitiaux, C, Thiele, S, Jungbluth, H, Audic, F, Potulska-Chromik, A, Marini-Bettolo, C, Davion, JB, de la Tassa, GM, Olivé, M, de la Hoz, CPDF, Isapof, A, Töpf, A, Walter, M, Angelini, C, Claeys, K, Kostera-Pruszczyk, A, Attarian, S, Straub, V, Domínguez-González, C, Vissing, J, Metay, C, Khraiche, D, Wahbi, K, Stojkovic, T. CLINICAL AND GENETIC SPECTRUM OF PATIENTS WITH BAG3-RELATED NEUROMUSCULAR DISORDERS IN EUROPE. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).